Managed Asset Portfolios LLC Buys 70,829 Shares of Sanofi $SNY

Managed Asset Portfolios LLC raised its stake in shares of Sanofi (NASDAQ:SNY) by 11.6% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 679,828 shares of the company’s stock after buying an additional 70,829 shares during the period. Sanofi comprises about 4.0% of Managed Asset Portfolios LLC’s portfolio, making the stock its 6th largest holding. Managed Asset Portfolios LLC’s holdings in Sanofi were worth $32,088,000 as of its most recent filing with the SEC.

Other hedge funds have also recently modified their holdings of the company. Brighton Jones LLC raised its position in Sanofi by 52.6% during the fourth quarter. Brighton Jones LLC now owns 5,420 shares of the company’s stock valued at $261,000 after acquiring an additional 1,869 shares in the last quarter. AQR Capital Management LLC grew its stake in shares of Sanofi by 107.2% during the 1st quarter. AQR Capital Management LLC now owns 30,518 shares of the company’s stock worth $1,693,000 after purchasing an additional 15,791 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Sanofi by 1.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,255 shares of the company’s stock valued at $2,732,000 after purchasing an additional 752 shares in the last quarter. Sivia Capital Partners LLC increased its holdings in shares of Sanofi by 5.4% during the 2nd quarter. Sivia Capital Partners LLC now owns 6,751 shares of the company’s stock valued at $326,000 after purchasing an additional 347 shares in the last quarter. Finally, Nisa Investment Advisors LLC lifted its stake in shares of Sanofi by 233.3% in the 2nd quarter. Nisa Investment Advisors LLC now owns 1,000 shares of the company’s stock valued at $48,000 after purchasing an additional 700 shares during the period. Hedge funds and other institutional investors own 14.03% of the company’s stock.

Sanofi Stock Down 2.5%

SNY stock opened at $46.47 on Wednesday. Sanofi has a 52 week low of $44.62 and a 52 week high of $60.12. The company has a quick ratio of 0.73, a current ratio of 1.09 and a debt-to-equity ratio of 0.20. The firm has a 50-day simple moving average of $47.49 and a 200-day simple moving average of $48.55. The stock has a market capitalization of $113.34 billion, a P/E ratio of 12.91, a P/E/G ratio of 1.23 and a beta of 0.45.

Analyst Ratings Changes

Several analysts recently commented on the stock. TD Cowen restated a “hold” rating on shares of Sanofi in a research report on Tuesday, December 30th. Wall Street Zen lowered shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 21st. JPMorgan Chase & Co. restated a “neutral” rating on shares of Sanofi in a research note on Monday, December 8th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Sanofi in a report on Friday, January 16th. Finally, UBS Group reissued a “neutral” rating on shares of Sanofi in a report on Friday, January 16th. Five analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $62.67.

About Sanofi

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.